CTNM Stock Summary and Trading Ideas (Contineum Therapeutics | NASDAQ:CTNM)

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Contineum Therapeutics trades on the NASDAQ stock market under the symbol CTNM.

As of September 11, 2026, CTNM stock price climbed to $15.19 with 5,082 million shares trading.

CTNM has a beta of 0.15, meaning it tends to be less sensitive to market movements. CTNM has a correlation of 0.00 to the broad based SPY ETF.

CTNM has a market cap of $571.46 million. This is considered a Small Cap stock.

The top ETF exchange traded funds that CTNM belongs to (by Net Assets): VTI, VXF, VTWO, SCHA, DFAS.

CTNM has outperformed the market in the last year with a return of +28.8%, while the SPY ETF gained +18.5%. In the last 3 month period, CTNM beat the market returning +34.4%, while SPY returned +5.7%. However, in the most recent 2 weeks CTNM has underperformed the stock market by returning -11.9%, while SPY returned -0.8%.

CTNM support price is $14.00 and resistance is $15.32 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CTNM shares will trade within this expected range on the day.